Jianmin Fu

This inventor holds 23 USPTO granted patents and 3 published patent applications and 19 EPO patents, primarily in Cancer Therapeutics. Top assignees: Merck Sharp + Dohme Corp., Msd R&d (China) Co., Ltd., Xrad Therapeutics, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jianmin Fu. Retrieved from https://idiyas.com/inventor/jianmin-fu-d0ljnvtv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 19 (Patent Applications = 19)

Average Co-Inventor Count = 11.0

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

22 out of 2,405

Merck Sharp + Dohme Corp.

patents

1 out of 10

Msd R&d (China) Co., Ltd.

patents

1 out of 1

Xrad Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

Areas of Expertise:

DNA-PK Inhibitors

Phosphatidylinositol 3-Kinase Delta

Guanylate Cyclase Stimulants

Metallo-Beta-Lactamase Inhibitors

PDE2 Inhibitors

Janus Kinase Inhibitors

Neurofibrillary Imaging Agents

Cysteine Protease Inhibitors

Purine Inhibitors

Triazolo Bicyclic Compounds

Dihydropyrazolopyrimidinone Compounds

Nucleoside Reverse Transcriptase Inhibitors

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187742 - Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy (2025-01-07),

2. 11179389 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2021-11-23),

3. 10780092 - Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators (2020-09-22),

4. 10544147 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2020-01-28),

5. 10544130 - Metallo-beta-lactamase inhibitors (2020-01-28),

6. 10428076 - Soluble guanylate cyclase stimulators (2019-10-01),

7. 10357481 - Substituted triazolo bicyclic compounds as PDE2 inhibitors (2019-07-23),

8. 10227331 - Metallo-β-lactamase inhibitors (2019-03-12),

9. 10221178 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2019-03-05),

10. 10221163 - Metallo-beta-lactamase inhibitors (2019-03-05),

11. 10160762 - 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors (2018-12-25),

12. 10100064 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-10-16),

13. 10072025 - Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors (2018-09-11),

14. 10059705 - Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors (2018-08-28),

15. 10030027 - Soluble guanylate cyclase stimulators (2018-07-24),

Title: Jianmin Fu: Innovator in Oncological Therapeutics

Introduction

Jianmin Fu is a distinguished inventor based in Beijing, China, known for his significant contributions to the field of oncology through innovative pharmaceutical compounds. With an impressive portfolio of 23 patents, Fu has dedicated his career to developing cutting-edge therapies aimed at combatting various oncologic diseases.

Latest Patents

Among his latest innovations, Jianmin Fu has created two notable patents:

1. **Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy** - This patent outlines compounds of Formula (I), (II), and (III) along with their pharmaceutically acceptable salts. These compounds are crucial for the development of pharmaceutical compositions aimed at treating oncologic diseases.

2. **Purine inhibitors of human phosphatidylinositol 3-kinase delta** - This invention provides compounds of formula I which function as PI3K-delta inhibitors. These compounds are beneficial for treating PI3K-delta-mediated diseases, including inflammation, asthma, chronic obstructive pulmonary disease (COPD), and cancer.

Career Highlights

Jianmin Fu has held significant roles at renowned companies including Merck Sharp & Dohme Corporation and MSD R&D (China) Co., Ltd. His work in these prestigious organizations has significantly advanced the field of pharmaceutical research and development.

Collaborations

Throughout his career, Jianmin has collaborated with industry peers such as Shimin Xu and Jason David Katz, demonstrating his commitment to teamwork and innovative research.

Conclusion

Jianmin Fu's dedication to developing novel therapeutic compounds underscores his status as a leading inventor in the realm of anti-cancer treatments. With a robust patent portfolio and a solid career foundation in reputable organizations, Fu’s contributions are paving the way for advancements in oncology and beyond.

Profile summary based on public USPTO records.